Drug – bio-affecting and body treating compositions – Inorganic active ingredient containing – Carbon disulfide – monoxide – or dioxide
Reexamination Certificate
2006-04-13
2008-03-04
Monshipouri, Maryam (Department: 1656)
Drug, bio-affecting and body treating compositions
Inorganic active ingredient containing
Carbon disulfide, monoxide, or dioxide
C514S012200, C252S372000
Reexamination Certificate
active
07338670
ABSTRACT:
The presently disclosed subject matter provides methods for increasing perfusion in hypoxic regions of tissues in subjects. Also provided are methods for treating diseases and/or disorders associated with hypoxia in subjects, methods for increasing sensitivity of tumors to radiation and/or chemotherapy treatments, methods for delaying tumor growth in subjects, and methods for inhibiting tumor blood vessel growth in subjects. In some embodiments, the presently disclosed methods involve administering to subjects in need thereof a first composition selected from the group consisting of a nitrosylated hemoglobin and an agent that induces nitrosylation of endogenous hemoglobin in the subject and a second composition comprising a hyperoxic gas. In some embodiments, the presently disclosed methods also include treating a tumor with radiation therapy, chemotherapy, photodynamic therapy, immunotherapy, or combinations thereof. Also provided are inhalable gases that can be employed in the presently disclosed methods.
REFERENCES:
patent: 5405940 (1995-04-01), Boon
patent: 5462871 (1995-10-01), Boon-Falleur
patent: 5695994 (1997-12-01), Boon-Falleur
patent: 6034214 (2000-03-01), Boon
patent: 6222012 (2001-04-01), Boon-Falleur
patent: 6314956 (2001-11-01), Stamler
patent: 6379901 (2002-04-01), Boon-Falleur
patent: 6488932 (2002-12-01), Boon
patent: 6676855 (2004-01-01), Stamler
patent: 6945247 (2005-09-01), Stamler et al.
patent: WO 94/05304 (1994-03-01), None
patent: WO 94/16713 (1994-08-01), None
patent: WO 95/25530 (1995-09-01), None
patent: WO 98/32855 (1995-12-01), None
patent: WO 96/29409 (1996-09-01), None
patent: WO 98/58956 (1998-12-01), None
Braun et al. Fourier analysis of fluctuations of oxygen tension and blood flow in R3230Ac tumors and muscle in rats.American Journal of Physiology, vol. 277, (1999), pp. H551-H568.
Chaux et al. Identification of five MAGE-A1 epitopes recorgnized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1.Journal of Immunology, vol. 163, (1999), pp. 2928-2936.
Comerford et al.Hypocia-inducible factor-1-dependent regulation of the Multidrug Resistancegene (MDRG). Cancer Research, vol. 62, (2002), pp. 3387-3394.
Dachs et al. Hypoxia modulated gene expression: angiogenesis, metastatis and therapeutic exproitation.European Journal of Cancer, vol. 36, (2000), pp. 1649-1660.
Dewhirst et al. Arteriolar oxygenation in tumor and subcutaneous arterioles: effects of inspired air oxygen content.British Journal of Cancer, vol. 74, (1996), pp. S241-246.
Dewhirst et al. Quantification of longitudinal tissue pO2 gradients in window chamber tumours: impact on tumour hypoxia.British Journal of Cancer, vol. 79, (1999), pp. 1717-1722.
Dolmans et al. Photodynamic therapy for cancer.Nature, vol. 3, (2003), pp. 380-387.
Gaugler et al. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes.Journal of Experimental Medicine, vol. 179, (1994), pp. 921-930.
Godelaine et al. Polyclonal CTL responses observed in melanoma patients vaccinated with dendritic cells pulsed with a MAGE-3.A1 peptide.The Journal of Immunology, vol. 171, (2003), pp. 4893-4897.
Goldstein, L.J. MDR1 gene expression in solid tumours.European Journal of Cancer, vol. 32A, No. 6, (1996), pp. 1039-1050.
Hill et al. Microregional blood flow in murine and human tumours assessed using laser Doppler microprobes.British Journal of Cancer, vol. 74, (1996), pp. S260-S263.
Kimura et al. Fluctuations in red cell flux in tumor microvessels can lead to transient hypoxia and reoxygenation in tumor parenchyma.Cancer Research, vol. 56, (1996), pp. 5522-5528.
Kinoshita et al. Cancer cells surviving hypoxia obtain hypoxia resistance and maintain anti-apoptotic potential under reoxygenation.International Journal of Cancer, vol. 91, (2001), pp. 322-326.
Le et al. Nitric oxide synthase II suppresses the growth and metastatis of human cancer regardless of its up-regulation of protumor factors.Proceedings of the National Academy of Sciences of USA, vol. 102, (2005), pp. 8758-8763.
Lewis et al. Macrophage responses to hypoxia. Implications for tumor progression and anti-cancer therapies.American Journal of Pathology, vol. 167, No. 3, (2005), pp. 627-635.
Moeller et al. Pleiotropic effects if HIF-1 blockade on tumor radiosensitivity.Cancer Cell, vol. 8, (2005), pp. 99-110.
Teicher at al. Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells.Cancer Research, vol. 41, (1981), pp. 73-81.
Teicher et al. Differenttial enhancement of melphalan cytotoxicity in tumor and normal tissue by Fluosol-DA® and oxygen breathing.International Journal of Cancer, vol. 36, (1995), pp. 585-589.
Tsai et al. Evidence of flowmotion induced changes in local tissue oxygenation.International Journal of Microcirculation: Clinical Experiment, vol. 12, (1993), pp. 75-88.
Van Baren et al. Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells.Journal of Clinical Oncology, vol. 23, No. 35, (2005), 9008-9021.
Van den Eynde et al. A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma.Journal of Experimental Medicine, vol. 182, (1995), pp. 689-698.
Vaupel et al. Oxygenation status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy.Seminars in Oncology, vol. 28, No. 2, Suppl. 8, (2001), pp. 29-35.
Dewhirst Mark W.
McMahon Timothy J.
Sonveaux Pierre
Stamler Jonathan S.
Duke University
Jenkins Wilson Taylor & Hunt, P.A.
Monshipouri Maryam
LandOfFree
Use of an agent that restores tissue perfusion and oxygenation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of an agent that restores tissue perfusion and oxygenation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of an agent that restores tissue perfusion and oxygenation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3965957